Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMNIRC)

Drug Name
N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine Drug Info
Synonyms
CHEMBL54860; N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine; SCHEMBL3023293; WBAIXNUCEGCLDC-UHFFFAOYSA-N; BDBM50138489; Methyl-(4-pyridin-3-yl-but-3-ynyl)-amine; N-Methyl-4-(3pyridinyl)-3-butyne-1-amine; 1-(3-Pyridinyl)-4-(methylamino)-1-butyne; N-Methyl-4-(3-pyridinyl)-3-butyne-1-amine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
15860335
TTD Drug ID
DMMNIRC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neuronal acetylcholine receptor alpha-4 (CHRNA4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trimethaphan DMHF4IQ Aneurysm BD51.Z Approved [2]
Pentolinium DM38VYQ Hypotension BA20-BA21 Approved [3]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [4]
ABT-594 DMGMBCW N. A. N. A. Discontinued in Phase 2 [5]
ABT-418 DMNP72I Alzheimer disease 8A20 Discontinued in Phase 2 [6]
HOMOEPIBATIDINE DMHP9WV N. A. N. A. Terminated [4]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [7]
Barbituric acid derivative DM2I19P Discovery agent N.A. Investigative [8]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS Discovery agent N.A. Investigative [9]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Neuronal acetylcholine receptor beta-2 (CHRNB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [4]
TC-5214 DM8AM60 Palmar hyperhidrosis EE00.00 Phase 2 [10]
SUVN-911 DMLPBVF Major depressive disorder 6A70.3 Phase 1 [11]
AZD-9684 DMHA5ME Thrombosis DB61-GB90 Discontinued in Phase 2 [12]
ABT-594 DMGMBCW N. A. N. A. Discontinued in Phase 2 [5]
ABT-418 DMNP72I Alzheimer disease 8A20 Discontinued in Phase 2 [13]
HOMOEPIBATIDINE DMHP9WV N. A. N. A. Terminated [4]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [7]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS Discovery agent N.A. Investigative [9]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuronal acetylcholine receptor alpha-4 (CHRNA4) TT4H1MQ ACHA4_HUMAN Inhibitor [1]
Neuronal acetylcholine receptor beta-2 (CHRNB2) TT5KPZR ACHB2_HUMAN Inhibitor [1]

References

1 Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6.
2 Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40.
3 Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6.
4 Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
5 The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13.
6 (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.
7 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
8 Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
9 Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
13 Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44.